Mesoblast appoints Shawn Cline Tomasello to Board

Company News

by Anna Napoli

Cellular medicine company, Mesoblast (ASX:MSB) has announced that Shawn Cline Tomasello has joined its Board of Directors.

She brings more than 30 years of experience in the pharmaceutical and biotech industries to the company.

Tomasello’s most recent position was with Kit Pharma, where she played a pivotel role in the company’s 2017 acquisition by Gilead Science.

Earlier this month, the company announced a $50 million financing agreement with NovaQuest Capital for the continued development and commercialization of its treatment for acute Graft versus host disease.

Shares in Mesoblast (ASX:MSB) are trading are trading 0.64 per cent lower to $1.55
 

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.